HALO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HALO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Halozyme Therapeutics's retained earnings for the quarter that ended in Dec. 2024 was $360 Mil.
Halozyme Therapeutics's quarterly retained earnings increased from Jun. 2024 ($261 Mil) to Sep. 2024 ($398 Mil) but then declined from Sep. 2024 ($398 Mil) to Dec. 2024 ($360 Mil).
Halozyme Therapeutics's annual retained earnings declined from Dec. 2022 ($143 Mil) to Dec. 2023 ($91 Mil) but then increased from Dec. 2023 ($91 Mil) to Dec. 2024 ($360 Mil).
The historical data trend for Halozyme Therapeutics's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Retained Earnings | Get a 7-Day Free Trial |
![]() |
![]() |
-474.59 | -58.91 | 143.22 | 90.55 | 359.87 |
Halozyme Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Retained Earnings | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
90.55 | 167.37 | 260.62 | 397.63 | 359.87 |
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Halozyme Therapeutics (NAS:HALO) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Jeffrey William Henderson | director | 7000 CARDINAL PLACE, DUBLIN OH 43017 |
Michael J. Labarre | officer: SVP, Chief Technical Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Helen Torley | director, officer: President and CEO | C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Matthew L. Posard | director | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Nicole Labrosse | officer: SVP, Chief Financial Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
James M Daly | director | INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880 |
Barbara Gayle Duncan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013 |
Akiko Moni Miyashita | director | 20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501 |
Mark Howard Snyder | officer: SVP, General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Matsui Connie | director | 3030 CALLAN RD, SAN DIEGO CA 92121 |
Jean-pierre Bizzari | director | 235 LAUREL LN, HAVERFOLD PA 19041 |
Kenneth J Kelley | director | 1331 HILLVIEW DRIVE, MENLO PARK CA 94025 |
Elaine D Sun | officer: SVP, Chief Financial Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Masaru Matsuda | officer: SVP, General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Benjamin Hickey | officer: SVP, Chief Commerical Officer | C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121 |
From GuruFocus
By GuruFocus News • 02-19-2025
By GuruFocus News • 02-04-2025
By PRNewswire • 02-04-2025
By GuruFocus News • 01-08-2025
By PRNewswire • 02-03-2025
By GuruFocus News • 03-04-2025
By GuruFocus News • 02-05-2025
By GuruFocus News • 12-30-2024
By GuruFocus News • 02-19-2025
By GuruFocus News • 02-18-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.